Working… Menu

A Study to Assess Whether Etrolizumab is a Safe and Efficacious Treatment for Participants With Moderately to Severely Active Crohn's Disease (BERGAMOT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02394028
Recruitment Status : Active, not recruiting
First Posted : March 20, 2015
Last Update Posted : July 7, 2021
Information provided by (Responsible Party):
Hoffmann-La Roche